Forte Biosciences Reports Positive Progress in Q2 2024; Advances FB102 Monoclonal Antibody Therapeutic Candidate
Forte Biosciences, Inc., a clinical-stage biopharmaceutical company headquartered in Dallas, has announced significant developments in its operations during the second quarter of 2024, along with comprehensive financial...
Aug 15, 2024
• Major Pharmaceutical Preparations Industry
Business Update
NASDAQ
